Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
170 participants
OBSERVATIONAL
2023-06-26
2024-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of an Intervention for Living With Mild Cognitive Impairment
NCT02083237
French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)
NCT03232697
Lariboisière Cognitive Assessment: Evaluation of the 1-year Outcomes
NCT06171568
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
NCT03811184
Efficacy of Multidimensional Management of Mild Traumatic Brain Injury
NCT03811626
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The general hypothesis is that the French version of the Mild Behavioral Impairment-Checklist (MBI-C) scale has good psychometric capabilities to correctly measure behavioral symptoms in patients with subjective cognitive complaint or MCI. The main objective is to verify the reliability and internal and external validity of the MBI-C score. Secondary objectives include studying the prevalence of MBI and determining the best cutoff for the diagnosis of MBI in patients with MBI or subjective cognitive complaint.
This is an observational, national, multicenter and cross-sectional study. It will include 170 patients (5 per scale item, or 34 items), with an inclusion period of 24 months and a total research duration of 25 months. Patients must be over 50 years old, have had subjective cognitive complaint or mild cognitive impairment for at least 6 months, and have a person who visits them at least once a week.
Validation of the MBI-C scale in French could play a crucial role in the identification and early management of neurodegenerative disorders.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MBI-C Scale in French
MBI-C Scale in French
The original version has 34 items, divided into 5 areas:
* a reduction in motivation, interests and initiative
* the appearance of mood disorders
* dysregulation of impulse management
* loss of conventions and societal norms
* the abnormal development of strongly held beliefs and sensory experiences
The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.
This scale is completed by a member of the healthcare team on the basis of information collected from the relative ("informant") either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.
The test lasts 10 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MBI-C Scale in French
The original version has 34 items, divided into 5 areas:
* a reduction in motivation, interests and initiative
* the appearance of mood disorders
* dysregulation of impulse management
* loss of conventions and societal norms
* the abnormal development of strongly held beliefs and sensory experiences
The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.
This scale is completed by a member of the healthcare team on the basis of information collected from the relative ("informant") either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.
The test lasts 10 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a relative visiting them at least once a week.
* No opposition from the patient and his loved one
Exclusion Criteria
* Neuropsychiatric symptoms secondary to concomitant treatments, or to a medical or psychiatric pathology.
* Concomitant major depressive episode (DSM-V).
* Presence of concomitant pathologies preventing participation in the study (taking tests).
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria SOTO
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Limoges
Limoges, , France
University Hospital Nice
Nice, , France
University Hospital Strasbourg
Strasbourg, , France
University Hospital Toulouse
Toulouse, , France
Univsersity Hospital Lyon
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/22/0323
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.